An investor remains broadly bearish on the stock market due to high valuations, record margin debt, and rising recession risks. However, they see selective buying opportunities in defense stocks like Lockheed Martin and Northrop Grumman, which appear oversold and serve as a hedge against geopolitical risks. The investor also favors Pfizer for its attractive 7% dividend yield and potential in AI-driven drug discovery, and KBR for its undervalued space division spinoff. They expect a correction in chip stocks due to AI capital expenditure fatigue and prefer to keep high cash levels for flexibility amid market uncertainty.
The Schwab U.S. Dividend Equity ETF (SCHD) continues to deliver a reliable and growing dividend stream, supported by a portfolio of companies with long histories of dividend payments and strong cash flows. Key holdings like Coca-Cola, Chevron, and Lo...
Lockheed Martin is positioned as a reliable long-term investment due to its $194 billion backlog and strong ties to U.S. government defense spending. Its key products like the F-35 and missile defense systems ensure decades of steady revenue, support...
The U.S. Space Force awarded SpaceX a $4.16 billion contract for the Space-Based Airborne Moving Target Indicator (SB-AMTI) program, aimed at creating a satellite network to track airborne threats. Alongside SpaceX, Rocket Lab, Lockheed Martin, and L...
The CEOs of Boeing, Lockheed Martin, and Honeywell met with President Trump as the administration urges defense contractors to increase weapons production due to concerns over U.S. missile and munitions stockpiles. This push follows recent U.S. milit...
